Anti-Hypertensive Drugs Global Market Report 2024

The anti-hypertensive drugs market size has grown steadily in recent years. It will grow from $35.8 billion in 2023 to $36.7 billion in 2024 at a compound annual growth rate (CAGR) of 2.5%. The growth observed in the historical period can be attributed to influences stemming from environmental and lifestyle factors, historical market competition, prevailing treatment preferences in the past, economic conditions, and trends in global health history.

The anti-hypertensive drugs market size is expected to see steady growth in the next few years. It will grow to $40.28 billion in 2028 at a compound annual growth rate (CAGR) of 2.4%. The projected growth in the forecast period can be attributed to factors such as cost-effectiveness and affordability, the emergence of therapeutic innovations, trends in epidemiology, regulatory changes and approvals, dynamics related to an aging population, and shifts in healthcare policies and reimbursement structures. Key trends anticipated in the forecast period encompass therapeutic innovation, changes in epidemiological patterns, shifts in the regulatory landscape, evolving healthcare policies, and advancements in diagnosis and monitoring.

A sedentary lifestyle stands out as a significant catalyst for the expansion of the anti-hypertensive drug market. The rise in hypertension can be attributed to factors such as the consumption of unhealthy junk food, inadequate adherence to a balanced diet, and irregular sleep patterns resulting from unconventional work shifts. These lifestyle elements contribute to an upsurge in hypertension, which, in turn, serves as a major precursor for 45% of heart disease-related deaths and 51% of stroke-related fatalities. As per World Health Organization (WHO) data from June 2021, cardiovascular diseases (CVDs) claim an estimated 17.9 million lives annually, making them the leading global cause of death. This sustained demand for anti-hypertensive drugs is a key driver fostering market growth.

The escalating prevalence of cardiovascular diseases is expected to drive future growth in the anti-hypertensive drugs market. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, with risk factors including smoking, high blood pressure, high cholesterol, diabetes, obesity, and a sedentary lifestyle. Anti-hypertensive drugs play a crucial role in managing and mitigating high blood pressure, a major risk factor for cardiovascular diseases in older adults. In October 2022, the National Library of Medicine projected that by 2035, 45.1% of the US population could have cardiovascular disease, with total costs reaching $1.1 trillion. Additionally, data from the World Heart Federation in May 2023 revealed 20.5 million deaths from cardiovascular diseases in 2021. Consequently, the increasing prevalence of cardiovascular diseases is propelling the expansion of the anti-hypertensive drugs market.

One significant impediment to the anti-hypertensive drugs market is the low awareness of these medications among the population. In developing nations, many individuals neglect regular health checkups, often remaining unaware of their hypertension until severe symptoms manifest. Moreover, diagnosed individuals exhibit low adherence to prescribed medication schedules, frequently discontinuing treatment after 1-2 weeks, leading to significant challenges for the anti-hypertensive drugs market. A research survey published by BMC Research from a developing country highlighted that only 17% of 112 hypertensive subjects with stroke were adherent to antihypertensive medications. Hence, lack of awareness and poor drug adherence pose constraints to the growth of the anti-hypertensive market.

Prominent companies in the anti-hypertensive drugs market are concentrating their efforts on introducing innovative products, including Metoprolol Succinate Extended-Release Tablets, to gain a competitive advantage. Metoprolol Succinate Extended-Release Tablets serve as anti-hypertensive drugs tailored for patients with hypertension. For example, in June 2023, Granules India Limited, a pharmaceutical manufacturing company based in India, unveiled Metoprolol Succinate Extended-Release Tablets, which received approval from the US Food and Drug Administration (FDA). These tablets, available in strengths ranging from 25mg to 200mg, function as beta-blockers, slowing down the heart rate, easing the workload on the heart, and ultimately lowering blood pressure.

In recent times, there has been a notable surge in the adoption of combination therapies compared to monotherapy for hypertension treatment. While monotherapy involves using a single drug, combination therapy utilizes a mix of drugs to target various hypertensive mechanisms concurrently. Combining two drugs with distinct mechanisms of action results in an effect two to five times greater than monotherapy. Studies indicate that increasing the dose of monotherapy leads to a 29% reduction in coronary events and a 40% reduction in cerebrovascular events. In contrast, combining two antihypertensive agents with different mechanisms of action achieves a more significant impact, reducing coronary events by 40% and cerebrovascular events by 54%. Consequently, the trend of employing combination therapy is gaining widespread acceptance due to its enhanced effectiveness.

The US Food and Drug Administration (FDA) has issued guidance regarding the development of fixed-combination drugs for hypertension. This guidance primarily focuses on the clinical development of two-drug combinations comprising previously approved products. The FDA anticipates a decrease in adverse effects for combinations that include doses below each drug's maximum dose compared to single drug regimens at their maximum dose. Current medical guidelines recommend initiating patients on two drugs at less than their full doses, marking a departure from the earlier practice of starting with a single drug and titrating up to the maximum dose before introducing additional drugs. This guidance is expected to regulate the development of fixed-combination drugs for hypertension.

Major companies operating in the anti-hypertensive drugs market report are Pfizer Inc., Johnson & Johnson Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbiVe Inc., Bayer AG, Novartis AG, Sanofi SA, Astra Zeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., C.H. Boehringer Sohn AG & Ko. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Company Limited, Fresenius Kabi AG, Sun Pharmaceuticals LLC, Cipla Limited, Dr. Reddy's Laboratories, Hikma Pharmaceuticals PLC, Lupin Limited, United Therapeutics, Torrent Pharmaceuticals Ltd., Ranbaxy Laboratories, Noden Pharma DAC, Acacia Pharma Group PLC, Actelion Pharmaceuticals Ltd. North America was the largest region in the anti-hypertensive drugs market in 2023. The Middle East is expected to be the largest growing region in the global anti-hypertensive drugs market during the forecast period. The regions covered in the anti-hypertensive drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The key therapeutic classes of anti-hypertensive drugs include diuretics, angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, alpha-blockers, calcium channel blockers, renin inhibitors, and vasodilators. Diuretics, commonly known as water pills, work by increasing the elimination of water and salt from the body through urine. Various sources of hypertension encompass primary and secondary hypertension, both of which are addressed through treatment modalities in hospitals, clinics, and home care settings.

The anti-hypertensive drugs market research report is one of a series of new reports that provides anti-hypertensive drugs market statistics, including anti-hypertensive drugs industry global market size, regional shares, competitors with an anti-hypertensive drugs market share, detailed anti-hypertensive drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-hypertensive drugs industry. This anti-hypertensive drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The countries covered in the anti-hypertensive drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-hypertensive drugs market consists of sales of thiazide-type diuretics, beta-blocker metoprolol, olmesartan, and HCTZ. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.